Evidence map›Paper›PMID 42312106›Full record

ArticleCase reports in oncology

Complete Response in Metastatic Rectal Cancer with Hepatic and Pulmonary Metastases Treated with Second-Line FOLFIRI plus Ramucirumab: A Case Report.

Makoto Hasegawa, Hirokazu Okayama, Yuki Kitabori, Naoto Yamauchi, Takahiro Nakajima, Susumu Matsumoto, Naoki Sato, Motonobu Saito, Koji Kono

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Makoto HasegawaDepartment of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
Hirokazu OkayamaDepartment of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
Yuki KitaboriDepartment of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
Naoto YamauchiDepartment of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
Takahiro NakajimaDepartment of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
Susumu MatsumotoDepartment of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
Naoki SatoDepartment of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
Motonobu SaitoDepartment of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
Koji KonoDepartment of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: In metastatic colorectal cancer (CRC), achieving complete response (CR) through chemotherapy alone is exceedingly rare. We report a case of metastatic CRC that achieved CR following second-line treatment with FOLFIRI plus ramucirumab after disease progression on first-line FOLFOX plus panitumumab therapy. Case Presentation: A 61-year-old woman was diagnosed with stage IVB rectal cancer with synchronous liver, lung, and lateral lymph node metastasis ( Conclusion: We report a rare case in which second-line FOLFIRI plus ramucirumab led to a CR in metastatic CRC, even after progression on anti-epidermal growth factor receptor therapy. In the present case, a watch-and-wait strategy was selected to prioritize organ preservation. Given the lack of consensus, further investigation is required to define the optimal strategy for patients achieving CR.

Indexed as

Colorectal cancerComplete responseDisappearing liver metastasesDisappearing lung metastasesRamucirumab

Identifiers

PMID42312106
PMCPMC13271689

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.